The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-05

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Use of indocyanine green will augment the accuracy of identification and resection of both primary solid malignancies as well as their pulmonary metastases, where applicable We will conduct a prospective feasibility study of pediatric patients with solid malignancies with or without lung metastatases who present at the time of initial diagnosis or relapse. These patients will receive a targeted dye to aid in the resection of these metastases. We plan to assess ICG as it relates to:

1. Diagnostic accuracy using pathologic correlation as gold standard measure
2. Short and long term event free and overall survival

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Application of 99mTc-FDPH46 SPECT/CT Imaging in Malignant Solid Tumor: a Prospective Exploratory Study

NCT06753513

Malignant Tumors Solid Tumor Malignancy

NOT_YET_RECRUITING

123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

NCT01373736

Pheochromocytoma Neuroblastoma Paraganglioma +2 more

UNKNOWN PHASE3

Indocyanine Green and Near-infrared Fluorescence Imaging to Detect Sentinel Lymph Nodes in Patients With Endometrial Cancer

NCT02131558

Endometrial Cancer Sentinel Lymph Node Detection

COMPLETED NA

Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas

NCT03054792

Rhabdomyosarcoma Non-Rhabdo. Soft Tissue Sarcoma

ENROLLING_BY_INVITATION PHASE1

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

NCT01869725

Adult Medulloblastoma Childhood Medulloblastoma Neuroblastoma +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients diagnosed with solid malignancies or metastatic lesions who require clinically indicated resection will be identified by their Oncologist. The oncologist will inform the subject/family about the study and ask if they may be interested in participating. If the subject/family demonstrates potential interest in the study, the Pediatric Surgery Research team will discuss the risks and benefits of pre-operative ICG administration with the patients and enrollment.

Study subjects: All patients diagnosed with solid malignancies as well as those with metastatic disease distant from the primary tumor will be potentially eligible for the study. Diagnosis will be made:

1. In a multimodal fashion including physical exam, radiologic evaluation (ultrasound, MRI, CT scan, etc), and sometimes biopsy.
2. Prior to definitive surgical resection of the newly diagnosed malignancy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Disease Primary Tumor Solid Malignancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All patients with newly diagnosed solid, primary malignancies or their related metastatic lesions.

Diagnosis of primary or metastatic malignancy will be made by combination of:

1. Clinical evaluation and physical exam
2. Radiologic study including ultrasound, CT scan, and/or MRI
3. Pathologic diagnosis after biopsy

Exclusion Criteria

1. Those patients and parents/guardians unwilling to provide consent/assent.
2. Pregnant and/or women who are breast feeding.
3. Patients with Iodine allergies

Minimum Eligible Age

1 Day

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No